pSivida to Present At Two Investment Conferences in September
04 September 2013 - 3:00PM
Business Wire
pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company
that is a leader in developing sustained release drugs for
treatment of back-of-the-eye diseases, will present at two upcoming
investor conferences in September.
pSivida will present at the Rodman & Renshaw Annual Global
Investment Conference being held at the Millennium Broadway Hotel
in New York on Tuesday, September 10 at 12:05 p.m. This
presentation will be webcast and can be found at the following
link: http://wsw.com/webcast/rrshq23/PSDV. Follow the official
Rodman & Renshaw handle on Twitter @rodman_2013 and use
#rodman2013 for conference information and updates.
pSivida will also present at the Stifel Nicolaus Healthcare
Conference being held at the Four Seasons Boston Hotel, in the
Winthrop Room, on Thursday, September 12 at 11:30 a.m. and will
also be webcast:
http://www.veracast.com/webcasts/stifel/healthcare2013/98207674667.cfm.
All times are Eastern.
About pSivida
pSivida Corp., headquartered in Watertown, MA, develops tiny,
sustained release, drug delivery products designed to deliver drugs
at a controlled and steady rate for months or years. pSivida is
currently focused on treatment of chronic diseases of the back of
the eye utilizing its core technology systems, Durasert™ and
BioSilicon™. The injectable, sustained release micro-insert
ILUVIEN® for the treatment of chronic DME considered insufficiently
responsive to available therapies, licensed to Alimera Sciences,
Inc., has received marketing authorization in Austria, France,
Germany, Portugal, Spain and the U.K. and is awaiting authorization
in Italy. Alimera has resubmitted the New Drug Application for
ILUVIEN for DME to the U.S. Food and Drug Administration. pSivida
plans to institute pivotal Phase III clinical trials for the
treatment of posterior uveitis, a chronic back-of-the-eye disease,
with the same micro-insert as ILUVIEN for DME. An
investigator-sponsored clinical trial is ongoing for an injectable,
bioerodible micro-insert to treat glaucoma and ocular hypertension.
pSivida's FDA-approved Retisert® licensed to Bausch & Lomb
Incorporated provides long-term, sustained drug delivery to treat
posterior uveitis.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995:
Various statements made in this release are forward-looking, and
are inherently subject to risks, uncertainties and potentially
inaccurate assumptions. All statements that address activities,
events or developments that we intend, expect or believe may occur
in the future are forward-looking statements. The following are
some of the factors that could cause actual results to differ
materially from the anticipated results or other expectations
expressed, anticipated or implied in our forward-looking
statements: uncertainties with respect to: determination of the
price and reimbursement conditions for ILUVIEN in France; Alimera's
ability to obtain regulatory approval for, and if approved, to
finance, successfully commercialize and achieve market acceptance
of, and generate revenues to pSivida from, ILUVIEN for DME in the
U.S.; Alimera's ability to finance, achieve additional marketing
approvals, achieve appropriate pricing and reimbursement and
successfully commercialize and achieve market acceptance of, and
generate revenues to pSivida from, ILUVIEN for DME in the EU; the
success of Phase III posterior uveitis trials including efficacy,
side effects and risk/benefit profile of the posterior uveitis
micro-insert and pSivida’s ability to finance and complete the
trials and receive marketing approvals; initiation, financing and
success of Latanoprost Product Phase II trials and exercise by
Pfizer of its option; development of products using Tethadur and
BioSilicon; initiation and completion of clinical trials and
obtaining regulatory approval of product candidates; adverse side
effects; ability to attain profitability; ability to obtain
additional capital; further impairment of intangible assets;
fluctuations in operating results; decline in royalty revenues;
ability to, and to find partners to, develop and market products;
termination of license agreements; competition and other
developments affecting sales of products; market acceptance;
protection of intellectual property and avoiding intellectual
property infringement; retention of key personnel; product
liability; consolidation in the pharmaceutical and biotechnology
industries; compliance with environmental laws; manufacturing
risks; risks and costs of international business operations; credit
and financial market conditions; legislative or regulatory changes;
volatility of stock price; possible dilution; possible influence by
Pfizer; absence of dividends; and other factors described in our
filings with the SEC. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward-looking
statements. Our forward-looking statements speak only as of the
dates on which they are made. We do not undertake any obligation to
publicly update or revise our forward-looking statements even if
experience or future changes makes it clear that any projected
results expressed or implied in such statements will not be
realized.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook:
https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+:
https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog:
http://www.thechairmansblog.com/paul-ashton
IN US:Martin E. Janis & Company, Inc.Beverly Jedynak,
President312-943-1123; 773-350-5793 (cell)bjedynak@janispr.comorIN
AUSTRALIA:pSivida Corp.Brian Leedman, Vice President, Investor
Relations+61 (0) 41 228 1780brianl@psivida.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024